A Nomogram for Predicting Sclerotherapy Response for Treatment of Lymphatic Malformations in Children

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2022 Oct 22

PMID 36271467

Authors

Zhiping Wu

Yun Zou

Ronghua Fu

Pingliang Jin

Hua Yuan

Affiliations

Soon will be listed here.

Abstract

Purpose: In this manuscript, we purposed to identify the prognostic factors for treatment of lymphatic malformations in children using polidocanol foam combined with pingyangmycin and to construct nomogram for predicting sclerotherapy response.

Methods: A retrospective analysis of 77 children having LMs who underwent sclerotherapy using polidocanol foam combined with pingyangmycin under ultrasound display from January 2017 to April 2020 was done. The clinical response was graded as excellent (≥ 90%), good (≥ 50%, < 90%), and poor (< 50%). More than 50% was considered as acceptable response. Prognostic factors were identified by Pearson's Chi-square or Fisher's exact test and multivariable logistic regression model was used to construct a nomogram to predict sclerotherapy response. The discrimination and calibration of nomogram were verified through the receiver operating characteristic cure and calibration plots.

Results: The mean number of treatment sessions was 3.1 (range, 1-6). Among 77 patients, 58 patients (75.3%) had excellent response to treatment (≥ 90%) and 68 patients (88.3%) had an acceptable response (≥ 50%, < 90%). Clinical disfigurement (P = 0.014), skin discoloration (P = 0.040), morphological subtype (P < 0.001) and extent of the lesion (P < 0.001) correlated with clinical response to sclerotherapy in LMs. Sclerotherapy response was predicted through nomogram constructed in this study, which shows good calibration and discrimination. Also, focal lesion and macrocystic or mixed morphological subtype lesion were seen more often in lower number of treatment sessions among the patients with excellent response.

Conclusions: An acceptable response to sclerotherapy using polidocanol foam combined with pingyangmycin was achieved in majority of LMs in children with extremely low complication rates. Nomogram based on the prognostic factors of sclerotherapy response for LMs in children was shown to possess an excellent performance to predict the probability of LMs sclerotherapy response.

Citing Articles

A new therapy for microcystic lymphatic malformations: the combination of intralesional laser thermolysis and percutaneous sclerotherapy.

Wu Z, Zou Y, Fu R, Cheng J, Bai H, Huang M Front Cell Dev Biol. 2025; 12():1490351.

PMID: 39777264 PMC: 11703971. DOI: 10.3389/fcell.2024.1490351.

References

Grasso D, Pelizzo G, Zocconi E, Schleef J . Lymphangiomas of the head and neck in children. Acta Otorhinolaryngol Ital. 2008; 28(1):17-20. PMC: 2640069. View

Wang Q, Zhou Q, Zhao Z, Liu C, Zheng J . Successful Sclerotherapy for Cervicofacial Macrocystic Lymphatic Malformations Using Polidocanol and Pingyangmycin Combined Foam Sclerosants. Lymphat Res Biol. 2022; 20(5):507-513. DOI: 10.1089/lrb.2021.0053. View

De Leacy R, Bageac D, Manna S, Gershon B, Kirke D, Shigematsu T . A Radiologic Grading System for Assessing the Radiographic Outcome of Treatment in Lymphatic and Lymphatic-Venous Malformations of the Head and Neck. AJNR Am J Neuroradiol. 2021; 42(10):1859-1864. PMC: 8562749. DOI: 10.3174/ajnr.A7260. View

De Corso E, Cina A, Salonna G, Di Cintio G, Gaudino S, Panfili M . Sclerotherapy with polidocanol microfoam in head and neck venous and lymphatic malformations. Acta Otorhinolaryngol Ital. 2021; 42(2):116-125. PMC: 9131995. DOI: 10.14639/0392-100X-N1310. View

Mai H, Zheng J, Zhou Q, Yang X, Wang Y, Fan X . Intralesional injection of pingyangmycin is a safe and effective treatment for microcystic lymphatic malformations in the tongue. Phlebology. 2012; 28(3):147-52. DOI: 10.1258/phleb.2011.011082. View

Horbach S, Lokhorst M, Saeed P, de Gouyon Matignon de Pontouraude C, Rothova A, van der Horst C . Sclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents. J Plast Reconstr Aesthet Surg. 2016; 69(3):295-304. DOI: 10.1016/j.bjps.2015.10.045. View

Wu H, Wang X, Zheng J, Zhao H, Ge J, Zhang L . Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin. Medicine (Baltimore). 2016; 95(37):e4790. PMC: 5402574. DOI: 10.1097/MD.0000000000004790. View

Kim D . OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome. Pediatr Radiol. 2014; 44(7):857-62. DOI: 10.1007/s00247-014-2889-0. View

Wang Jr H, Xie C, Lin W, Zhou J, Yang W, Guo Z . Liposuction-Like Sclerotherapy Technique for Microcystic Lymphatic Malformation. Cureus. 2022; 14(3):e22795. PMC: 8896249. DOI: 10.7759/cureus.22795. View

10.

Pessanha I, Bravo M, Piedade C, Lopes M . Complex lymphatic malformations in pediatrics: a review of treatment options. Minerva Pediatr (Torino). 2022; 74(1):70-80. DOI: 10.23736/S2724-5276.20.06037-5. View

11.

de Serres L, Sie K, Richardson M . Lymphatic malformations of the head and neck. A proposal for staging. Arch Otolaryngol Head Neck Surg. 1995; 121(5):577-82. DOI: 10.1001/archotol.1995.01890050065012. View

12.

Yamaki T, Sasaki Y, Hasegawa Y, Osada A, Konoeda H, Hamahata A . Percutaneous ultrasound-guided sclerotherapy with polidocanol microfoam for lymphatic malformations. J Vasc Surg Venous Lymphat Disord. 2017; 5(5):707-714. DOI: 10.1016/j.jvsv.2017.03.017. View

13.

Meurisse V, Denamur S, Herbreteau D, Le Touze A, Favrais G, Pondaven-Letourmy S . Efficacy of sirolimus combined with sclerotherapy for giant cervical lymphatic macrocystic malformations: two newborn cases. Eur J Dermatol. 2019; 29(1):90-91. DOI: 10.1684/ejd.2018.3441. View

14.

McCormack L, Jones K, Huang J . Micro- and Macrocystic Lymphatic Malformation. J Pediatr. 2020; 219:275-276. DOI: 10.1016/j.jpeds.2019.12.004. View

15.

Markovic J, Nag U, Shortell C . Safety and efficacy of foam sclerotherapy for treatment of low-flow vascular malformations in children. J Vasc Surg Venous Lymphat Disord. 2020; 8(6):1074-1082. DOI: 10.1016/j.jvsv.2019.11.023. View

16.

Christison-Lagay E . Complications in head and neck surgery. Semin Pediatr Surg. 2016; 25(6):338-346. DOI: 10.1053/j.sempedsurg.2016.10.007. View

17.

Lam S, Yuen H . Medical and sclerosing agents in the treatment of orbital lymphatic malformations: what's new?. Curr Opin Ophthalmol. 2019; 30(5):380-385. DOI: 10.1097/ICU.0000000000000585. View

18.

Wang Y, Li X . [The diagnosis and treatment progress of lymphatic malformations of the head and neck in children]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015; 29(11):1049-52. View

19.

Yun W, Kim Y, Lee K, Kim D, Park K, Kim K . Predictors of response to percutaneous ethanol sclerotherapy (PES) in patients with venous malformations: analysis of patient self-assessment and imaging. J Vasc Surg. 2009; 50(3):581-9, 589.e1. DOI: 10.1016/j.jvs.2009.03.058. View

20.

Luo Q, Gan Y . Pingyangmycin with triamcinolone acetonide effective for treatment of lymphatic malformations in the oral and maxillofacial region. J Craniomaxillofac Surg. 2012; 41(4):345-9. DOI: 10.1016/j.jcms.2012.10.022. View